Johnson & Johnson (NYSE:JNJ): Current price $83.82
According to data being presented at a medical meeting in Europe, Johnson & Johnson’s Stelara exhibited significant improvement in signs and symptoms of psoriatic arthritis through 52 weeks of treatment in a late stage evaluation. The Phase III trial tested Stelara at two doses versus a placebo in 312 patients having active psoriatic arthritis, and included both subjects who had previously been treated with widely prescribed biotech drugs from the class named anti-TNF medicines and those who had not. J&J had previously posted results through 24 weeks of treatment in which almost 44 percent of those who received Stelara at either dose achieved ACR 20 compared to 20.2 percent who reached ACR 20 in the placebo group. The result was considered to be highly statistically significant.